Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.

Villanueva, C; Chaigneau, L; Dufresne, A; Thierry Vuillemin, A; Stein, U; Demarchi, M; Bazan, F; N'guyen, T; Pivot, X

Villanueva, C; Chaigneau, L; Dufresne, A; Thierry Vuillemin, A; Stein, U; Demarchi, M; Bazan, F; N'guyen, T; Pivot, X.

Affiliation

Villanueva C; Centre Hospitalier Universitaire de Besançon, Service d'Oncologie Médicale, 25030 Besancon cedex, France. cvillanueva@chu-besancon.fr

Breast ; 20(4): 329-33, 2011 Aug.

Article in En | MEDLINE | ID: mdl-21439823

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Breast Neoplasms/drug therapy; Paclitaxel/administration & dosage; Aged; Antineoplastic Agents, Phytogenic/administration & dosage; Antineoplastic Agents, Phytogenic/adverse effects; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Breast Neoplasms/pathology; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel/adverse effects; Tegafur/administration & dosage; Tegafur/adverse effects; Treatment Outcome; Uracil/administration & dosage; Uracil/adverse effects

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Paclitaxel Type of study: Clinical_trials Limits: Aged / Female / Humans / Middle aged Language: En Journal: Breast Journal subject: ENDOCRINOLOGIA / NEOPLASIAS Year: 2011 Document type: Article Affiliation country: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google